Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of bimekizumab in active psoriatic arthritis
jRCT2080224964Phase 3Completed
- Sponsor
- UCB
- Start
- Nov 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label, single-arm trial of bimekizumab in psoriatic arthritis (PsA), sponsored by UCB. Started Nov 2019; status: completed.
02
Drugs
bimekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on jRCT2080224964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224964.